The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.

Description

The purpose of the Texas Immuno-Oncology Biorepository (TIOB) is to collect and store well-defined and well-annotated serial biospecimens of tissue, blood, urine and stool in a longitudinal manner from cancer patients who are receiving either standard of care surgical interventions and or FDA approved immunotherapeutics across the largest not-for-profit health system in Texas. Comprehensive clinical and radiological data from a diverse population of patients with different racial, social and ethnic backgrounds matched with serial biospecimens over a patients journey with cancer marks the TIOB as a unique research facility.

Conditions

Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the Texas Immuno-Oncology Biorepository (TIOB) is to collect and store well-defined and well-annotated serial biospecimens of tissue, blood, urine and stool in a longitudinal manner from cancer patients who are receiving either standard of care surgical interventions and or FDA approved immunotherapeutics across the largest not-for-profit health system in Texas. Comprehensive clinical and radiological data from a diverse population of patients with different racial, social and ethnic backgrounds matched with serial biospecimens over a patients journey with cancer marks the TIOB as a unique research facility.

The Texas Immuno-Oncology Biorepository: Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers That Predict Benefit/Resistance to Cancer Therapeutics.

The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

Dallas

Baylor Scott & White Research Institute, Dallas, Texas, United States, 75246

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Understand and willingness to sign written informed consent method.
  • * Patients who are suspected by a physician of being at risk for developing cancer.
  • * Patients with confirmed or clinically suspected malignancy by a physician. This includes but is not limited to candidates for immunotherapy, surgical candidates, patients receiving Standard of Care drugs, immunotherapy drugs, participating on a clinical trial with immunotherapy drugs, patients who have received immunotherapy drugs in the past, patients with any other approved or investigational disease management.
  • * Patients unwilling to donate blood
  • * Patients unwilling to provide informed consent for the collection of fresh or archived tumor tissue.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Baylor Research Institute,

Ronan Kelly, MD, PRINCIPAL_INVESTIGATOR, Baylor Scott & White Research Institute

Study Record Dates

2052-09-11